This site uses cookies to simplify and improve your online experience.  You can find out more about cookies and how you can disable them by reading our Terms and Conditions. By continuing to browse this site you agree to our use of cookies on this device.

Close
Roche Navigation Menu Roche Resources : Roche Resources
  • Sign in
  • Logout
  • Search
Roche
  • Up
  • Home
  • Search
  • Close search

						
							

Searching

    • Home
    • Roche Medicines
      Roche Medicines Overview
      • Oncology
      • Avastin® (bevacizumab)
      • Kadcyla® (trastuzumab emtansine)
      • PERJETA® (pertuzumab)
      • PHESGO®▼(pertuzumab/trastuzumab)
      • TECENTRIQ®▼ (atezolizumab)
      • Rozyltrek▼(entrectinib)
      • Neuroscience
      • OCREVUS®▼ (ocrelizumab)
      • Immunology
      • RoACTEMRA® (tocilizumab)
      • Haematology
      • Gazyvaro® (obinutuzumab)
      • POLIVY®▼ (polatuzumab vedotin)
      • Rare Diseases
      • HEMLIBRA®▼ (emicizumab)
    • Therapy Areas
      Therapy Areas Overview
      • Oncology
      • Breast Cancer
      • Haematology
      • Haematology
      • Neuroscience
      • Neuroscience
    • Congress and Meetings
      Congress and Meetings Overview
    • HCP Materials
      HCP Materials Overview
    • FAQs
      FAQs Overview
    • Prescribing Information
      Prescribing Information Overview
      • Find out more about:
      • ALECENSA®▼(alectinib)
      • Avastin® (bevacizumab)
      • Esbriet® (pirfenidone)
      • GAZYVARO® (obinutuzumab)
      • HEMLIBRA®▼(emicizumab)
      • Herceptin® (trastuzumab) IV
      • Herceptin® (trastuzumab) SC
      • Kadcyla® (trastuzumab emtansine)
      • OCREVUS®▼ (ocrelizumab)
      • Perjeta® (pertuzumab)
      • Phesgo®▼(pertuzumab/trastuzumab)
      • Polivy®▼(polatuzumab vedotin)
      • RoACTEMRA® (tocilizumab) RA/GCA
      • RoACTEMRA® (tocilizumab) pJIA/sJIA
      • RoACTEMRA® (tocilizumab) CRS
      • Rozlytrek® ▼(entrectinib)
      • Tecentriq®▼ (atezolizumab) HCC
      • Tecentriq®▼ (atezolizumab) Lung Cancer
      • Tecentriq®▼ (atezolizumab) mTNBC
      • Tecentriq®▼ (atezolizumab) mUC
    • Adverse Events Reporting
      Adverse Events Reporting Overview
    Close

    1 - of results for ""

    No results

    This website is intended for healthcare professionals (HCPs) only. If you are an HCP, register free to access the full content.


    You are here:

    1. Resources
    2. Congresses and Meetings
    3. EHA 2020

    EHA 2020 virtual congress

    “...It was a different EHA this year being virtual but it was great to see such interesting and potentially practice changing or at least practice informing data coming out in EHA 25.”

    Dr Graham Collins, Lymphoma Lead (Oxford University Hopsitals)

    Developed and funded by Roche Products Limited.

    This year’s European Haematology Association (EHA) congress took place in a virtual setting from 11th - 21st June. Key haematology data from a UK perspective were chosen by a Steering Committee of four haematology experts. Insights from the Steering Committee are provided in the summary below.

    Steering Committee Highlights

    • Panel discussion and relevance to UK practice

      Dr George Follows facilitates a panel discusion with Dr Graham Collins, Prof Andy Davies and Dr Ruth Pettengell using Zoom webinar technology.

      The panel discuss key highlights in high grade, indolent and Hodgkin lymphoma. Duration 27 min.

      EHA abstracts are available on the EHA website until 15th October 2020

    • High grade lymphoma highlights
      Prof Andy Davies discusses his key takeaways on high grade lymphoma. Duration 16 min.
    • Indolent lymphoma highlights
      Dr Ruth Pettengell discusses her key takeaways on indolent lymphoma. Duration 10 min.
    • Hodgkin lymphoma highlights
      Dr Graham Collins discusses his key takeaways on Hodgkin lymphoma. Duration 19 min.
    • Chronic lymphocytic leukaemia highlights
      Dr George Follows discusses his key takeaways on chronic lymphocytic leukaemia. Duration 7 min.

    References:

    1. Borchmann P. S101 EHA 2020
    2. Byrd J C. S163 EHA 2020
    3. Carlo-Stella C. S233 EHA 2020
    4. Driessen J. et al S221 EHA 2020
    5. Eichenauer D. S220 EHA 2020
    6. Ghia P. S159 EHA 2020
    7. Ghosh N. S244 EHA 2020
    8. Held G. S230 EHA 2020
    9. Kater A P. S156 EHA 2020

     

    10. Kreissl S. S222 EHA 2020
    11. Kuhnl A. S243 EHA 2020
    12. Lindblad A A. S227 EHA 2020
    13. Osborne W. S240 EHA 2020
    14. Phillips E. S232 EHA 2020
    15. Pinczes L. et al EP1133 EHA 2020
    16. Rai S. et al EP1179 EHA 2020
    17. Rummel M. J et al EP1161 EHA 2020
    18. Rusconi C. S229 EHA 2020

     

    19. Siddiqi T. S158 EHA 2020
    20. Townsend W. et al EP1170 EHA 2020
    21. Trotman J. et al EP1158 EHA 2020
    22. Wilson M. S236 EHA 2020
    23. Zheng S. et al EP1129 EHA 2020
    24. Zinzani P L. et al EP1171 EHA 2020
    25. Zinzani P L. S238 EHA 2020
    26. Zinzani P L. et al LB2600 EHA 2020

    M-GB-00000760
    Date of preparation July 2020

    Welcome to Roche Resources

    Roche Resources is intended for UK Healthcare Professionals only. By entering this site you are confirming that you are a UK Healthcare professional.

    I am a healthcare professional I am a member of the public
    • © 2021 Roche Products Limited
    • 19.01.2021
    • Terms and Conditions
    • Privacy Policy
    • Prescribing Information
    • Contact

    Adverse events should be reported. Reporting forms and information can be found at www.mhra.gov.uk/yellowcard or search for MHRA Yellow Card in the Google Play or Apple App Store. Adverse events should also be reported to Roche Products Ltd. Please contact Roche Drug Safety Centre by emailing welwyn.uk_dsc@roche.com or calling +44 (0)1707 367554. ▼Additional monitoring: Medicinal products associated with this symbol are subject to additional monitoring. Reporting suspected adverse reactions after authorisation of the medicinal product is important. It allows continued monitoring of the benefit/risk balance of the medicinal product. For biological medicines, healthcare professionals should report adverse reactions by brand name and batch number. This is a promotional website intended for HCPs, designed, built and funded by Roche Products Ltd. Commentary and other materials, including external links, posted on this site are not intended to amount to advice on which reliance should be placed. We therefore disclaim all liability and responsibility arising from any reliance placed on such materials by any visitor to our site, or by anyone who may be informed of any of its contents. M-GB-00002434 Date of Preparation January 2021.